Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3469-3477

  Grimminger, Peter P ^a   Danenberg, Peter ^d   Dellas, Kathrin ^b   Arnold, Dirk ^b   Rödel, Claus ^c   Machiels, Jean Pascal ^f   Haustermans, Karin ^g   Debucquoy, Annelies ^g   Velenik, Vaneja ^h   Sempoux, Christine ^f   Bracko, Matej ^g   Hölscher, Arnulf H ^a   Semrau, Robert ^a   Yang, Dongyun ^e   Danenberg, Kathleen ^d   Lenz, Heinz Josef ^e   Vallböhmer, Daniel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Response Genetics Inc   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTAMIC ACID; MESSENGER RNA; OXALIPLATIN; THYMIDYLATE SYNTHASE; VALINE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHEMORADIOTHERAPY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY; TISSUE SECTION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79956014003     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2273     Document Type: Article

References (34)

1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23. (Pubitemid 44394918)
2. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon- Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. (Pubitemid 46630960)
3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8. (Pubitemid 350106711)
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
7. Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5- FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009;73:466-72.
8. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Strobel P, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009;74:1487-93.
9. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007;18:738-44. (Pubitemid 46523279)
10. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1081-6. (Pubitemid 351296110)
11. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-7. (Pubitemid 350003058)
12. Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 2010;36:244-50.
13. Semrau R, Vallbohmer D, Kocher M, et al. Pre-operative radio-chemoimmunotherapy with cetuximab and 5-FU in patients with locally advanced rectal cancer. First results of a phase I/II trial. Proceedings of the Annual Meeting of the German and Austrian Society of Radiooncology ; 2008; Vienna (abstract 169).
14. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)
15. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 2007;8:1705-13.
16. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481, 1483.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
18. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91. (Pubitemid 34753602)
19. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001. (Pubitemid 26388092)
20. Halpern J. Maximally selected chi-square statistics for small samples. Biometrics 1982;38:1017-23. (Pubitemid 14272809)
21. Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982;38:1011-6.
22. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-8.
23. Ruzzo A, Graziano F, Canestrari E, Magnani M. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Curr Cancer Drug Targets 2010;10:68-79.
24. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35. (Pubitemid 30395817)
25. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-93. (Pubitemid 38174017)
26. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005;23:3536-44.
27. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006;17:835-41.
28. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
29. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010;46:2781-7.
30. Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;27:2751-7.
31. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009;20:469-74.
32. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010;251:254-60.
33. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
34. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, et al. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 2006;8:76-83. (Pubitemid 43257437)